THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) and Onyx Pharmaceuticals, Inc. (ONXX) Wednesday said the waiting period for Amgen's proposed acquisition of Onyx, was terminated early on September 18, by the U.S Federal Trade Commission.
Amgen earlier announced agreement to acquire Onyx for $125 per share in cash, with the transaction to be effected through a tender offer. The waiting period was scheduled to expire on September 23.
The termination of the HSR waiting period satisfies one of the conditions to consummate the tender offer. Other closing conditions, including a minimum tender of at least a majority of outstanding Onyx shares, is yet to be satisfied.
Copyright RTT News/dpa-AFX
Kostenloser Wertpapierhandel auf Smartbroker.de